Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry-Reference-Cited by-同舟云学术

Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry

Published:2020-10 Issue: Volume:316 Page:229-235
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

De Luca Leonardo,Arca Marcello,Temporelli Pier Luigi,Meessen Jennifer,Riccio Carmine,Bonomo Paolo,Colavita Angela Rita,Gabrielli Domenico,Gulizia Michele Massimo,Colivicchi Furio

Funder

Heart Care Foundation

ANMCO Research Centre Heart Care Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS);Mach;Eur. Heart J.,2019

2. ESC scientific document group. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias;Catapano;Eur. Heart J.,2016

3. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Mihaylova;Lancet,2012

4. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials;Fulcher;Lancet,2015

5. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis;Navarese;JAMA,2018

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of dyslipidemia after atherosclerotic cardiovascular event: Still a long way to go…and we know it;International Journal of Cardiology;2024-07

2. Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on the simplification of the drug regimen for secondary cardiovascular prevention;European Heart Journal Supplements;2024-04

3. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry;Nutrition, Metabolism and Cardiovascular Diseases;2023-11

4. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study;The Lancet Regional Health - Europe;2023-08

5. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients;Wiener klinische Wochenschrift;2023-06-08